Literature DB >> 9374040

AIDS and the death receptors.

M E Peter1, A Ehret, C Berndt, P H Krammer.   

Abstract

Activation-induced cell death (AICD) of T cells involves the CD95 receptor/ligand system. T cell activation through the T cell receptor results in expression of the CD95 ligand (CD95L) that acts on CD95+ cells by direct binding and in a paracrine or autocrine fashion. In AIDS, upregulation of CD95L in T cells is accelerated by two viral gene products, HIV-1 Tat and gp120. The CD95 signaling pathway is, therefore, likely to represent an important road to cell death of the CD4+ T cells in AIDS. Recently, the early events in the CD95 signaling pathway have been identified. A key role hereby plays a receptor-interacting member of the interleukin 1 beta-converting enzymes (ICE), FLICE, that could be a target for therapeutic intervention. In addition to CD95, the role of other members of the TNF receptor superfamily in AIDS is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374040     DOI: 10.1093/oxfordjournals.bmb.a011633

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  4 in total

1.  Apoptosis in gingival overgrowth tissues.

Authors:  A Kantarci; P Augustin; E Firatli; M C Sheff; H Hasturk; D T Graves; P C Trackman
Journal:  J Dent Res       Date:  2007-09       Impact factor: 6.116

Review 2.  Genetic variation and function of the HIV-1 Tat protein.

Authors:  Cassandra Spector; Anthony R Mele; Brian Wigdahl; Michael R Nonnemacher
Journal:  Med Microbiol Immunol       Date:  2019-03-05       Impact factor: 3.402

3.  Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.

Authors:  Christos Tsoukas; Louise Gilbert; Trevor Lewis; George Hatzakis; Ron Falcon; Joseph Mrus
Journal:  ISRN AIDS       Date:  2013-12-12

Review 4.  The enduring tale of T cells in HIV immunopathogenesis.

Authors:  Madhu Vajpayee; Neema Negi; Sravya Kurapati
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.